<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024799</url>
  </required_header>
  <id_info>
    <org_study_id>QYFYKYLL931311920</org_study_id>
    <nct_id>NCT05024799</nct_id>
  </id_info>
  <brief_title>Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation</brief_title>
  <official_title>Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients in ICU are treated with a combination of analgesics and sedatives in most&#xD;
      cases. Due to the different mechanism of different sedative and analgesic drugs, different&#xD;
      antagonistic or synergistic effects may occur when combined with drugs, resulting in&#xD;
      different clinical effects, especially significant effects on ventilators for patients with&#xD;
      assisted breathing. Therefore, this study hopes to compare the effects of different sedative&#xD;
      and analgesic drug combinations on the duration of mechanical ventilation for patients with&#xD;
      ventilators, so as to guide the clinical adoption of a more reasonable sedative and analgesic&#xD;
      scheme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventilator-free days at 28 days</measure>
    <time_frame>at 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>F-P group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the combination of fentanyl and propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F-D group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the combination of fentanyl and dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-P group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the combination of butorphanol and propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-D group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the combination of butorphanol and dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl, propofol</intervention_name>
    <description>The patients in this group will be administered with fentanyl and propofol</description>
    <arm_group_label>F-P group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl and dexmedetomindine</intervention_name>
    <description>The patients in this group will be administered with fentanyl and dexmedetomindine</description>
    <arm_group_label>F-D group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butorphanol and propofol</intervention_name>
    <description>The patients in this group will be administered with butorphanol and propofol</description>
    <arm_group_label>B-P group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butorphanol and dexmedetomindine</intervention_name>
    <description>The patients in this group will be administered with butorphanol and dexmedetomindine</description>
    <arm_group_label>B-D group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults who are treated with sedation and analgesia for invasive mechanical ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  they have baseline severe cognitive impairment; were pregnant or breast-feeding; were&#xD;
             blind, deaf ; had second-degree or third-degree heart block or bradycardia requiring&#xD;
             intervention; had an allergy to the experimental drugs; had an indication for&#xD;
             benzodiazepines; were anticipated to have immediate discontinuation of mechanical&#xD;
             ventilation; were expected to have neuromuscular blockade for more than 48 hours; were&#xD;
             in a moribund state; or had received mechanical ventilation for more than 96 hours&#xD;
             before meeting all inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinyan Xing, Dr</last_name>
    <phone>86-0532-82919386</phone>
    <phone_ext>82919386</phone_ext>
    <email>xingjy@qdu.edu.cn</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital of Qingdao University</investigator_affiliation>
    <investigator_full_name>JinyanXing</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Butorphanol</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

